New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
04:55 EDTEXEL, EXEL, EXEL, AGIO, AGIO, AGIO, ALNY, ALNY, ALNY, EPZM, EPZM, EPZM, INFO, INFO, INFO, VRTX, VRTX, VRTX, FMI, FMI, FMIBernstein to hold a conference
Emerging Biotech Conference 2014 is being held in Snowbird, Utah on March 10-12.
News For EXEL;AGIO;ALNY;EPZM;INFO;VRTX;FMI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2015
08:18 EDTALNYAlnylam data encouraging, says JMP Securities
Subscribe for More Information
April 13, 2015
11:02 EDTALNYAlnylam publishes pre-clinical results on ALN-AT3
Subscribe for More Information
10:15 EDTALNYHigh option volume stocks
Subscribe for More Information
April 10, 2015
10:22 EDTFMIOptions with decreasing implied volatility
Subscribe for More Information
07:45 EDTVRTXVertex initiated with a Buy at Canaccord
Target $150.
April 9, 2015
10:48 EDTVRTXDeutsche compares PTC Therapeutics to Vertex, boosts target by $40
Subscribe for More Information
10:32 EDTFMIOptions with decreasing implied volatility
Subscribe for More Information
08:32 EDTEXELExelixis' cabozantinib granted FDA fast track designation
Exelixis announced that the U.S. Food & Drug Administration has granted Fast Track designation to cabozantinib for treatment of patients with advanced renal cell carcinoma who have received one prior therapy. Cabozantinib is the company’s lead compound and inhibits the activity of multiple tyrosine kinases including MET, VEGFRs and RET. The FDA created the Fast Track process to facilitate the development and expedite the review of drugs to treat serious diseases and address unmet medical needs. Fast Track designation confers important benefits, including the potential eligibility for Priority Review of a New Drug Application, if relevant criteria are met.1 Cabozantinib is the subject of METEOR, an ongoing phase 3 pivotal trial in patients with metastatic RCC who have experienced disease progression following treatment with at least one VEGFR tyrosine kinase inhibitor. Patients are randomized 1:1 to receive 60 mg of cabozantinib daily or 10 mg of everolimus daily. The primary endpoint of METEOR is progression-free survival, and secondary endpoints include overall survival and objective response rate. Exelixis expects to release top-line results from the trial in the second quarter of 2015. In addition to the metastatic RCC development program, Exelixis is also evaluating cabozantinib in CELESTIAL, a phase 3 pivotal trial in second-line hepatocellular carcinoma.
07:27 EDTVRTXPTC Therapeutics price target raised to $115 from $75 at Deutsche Bank
Subscribe for More Information
April 8, 2015
11:22 EDTFMIOptions with decreasing implied volatility
Subscribe for More Information
11:07 EDTFMIOptions with decreasing implied volatility
Subscribe for More Information
06:57 EDTALNYAlnylam added to short-term buy list at Deutsche Bank
April 7, 2015
11:09 EDTFMIOptions with decreasing implied volatility
Subscribe for More Information
08:24 EDTAGIOAgios Pharmaceuticals has a conference call hosted by JPMorgan
JPMorgan Analysts Kasimov, Fye and Rama will host a conference call with CEO David Schenkein on April 13 at 1 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use